

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6981779

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
CORTLAND CAPITAL MARKET SERVICES LLC	07/27/2016

RECEIVING PARTY DATA

Name:	KADMON CORPORATION, LLC
Street Address:	450 EAST 29TH STREET
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10016

PROPERTY NUMBERS Total: 24

Property Type	Number
Application Number:	11884811
Application Number:	12570153
Application Number:	11887218
Application Number:	12438504
Application Number:	12836414
Application Number:	11407500
Patent Number:	7745587
Patent Number:	8106168
Application Number:	13335185
Patent Number:	8183008
Application Number:	13454534
Patent Number:	8147836
Application Number:	13338622
Application Number:	12429338
Application Number:	13124046
Application Number:	61549873
Application Number:	13078344
Application Number:	11659582
Patent Number:	5705528
Patent Number:	RE39682

PATENT

Property Type	Number
Patent Number:	6462086
Patent Number:	6946485
Application Number:	12519578
Application Number:	12690174

CORRESPONDENCE DATA

Fax Number: (215)656-2498
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Phone: 215-656-3381
Email: pto.phil@dlapiper.com
Correspondent Name: IP GROUP OF DLA PIPER LLP (US)
Address Line 1: ONE LIBERTY PLACE
Address Line 2: 1650 MARKET ST. SUITE 5000
Address Line 4: PHILADELPHIA, PENNSYLVANIA 19103

ATTORNEY DOCKET NUMBER:	378635-000094 T.RASPA
NAME OF SUBMITTER:	WILLIAM L. BARTOW
SIGNATURE:	/William L. Bartow/
DATE SIGNED:	10/21/2021

Total Attachments: 22

source=Kadmon_Cortland- Patent Security Release(185727589.1)#page1.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page2.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page3.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page4.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page5.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page6.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page7.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page8.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page9.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page10.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page11.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page12.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page13.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page14.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page15.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page16.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page17.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page18.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page19.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page20.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page21.tif
source=Kadmon_Cortland- Patent Security Release(185727589.1)#page22.tif

Termination and Release of Patent Security Interest

This **Termination and Release of Patent Security Interest** (the “Release”), effective nunc pro tunc as of July 27, 2016 (the “Effective Date”), is made by CORTLAND CAPITAL MARKET SERVICES LLC (the “Administrative Agent”) in favor of KADMON CORPORATION, LLC, a Delaware limited liability company (the “Grantor”). Grantor and Administrative Agent are sometimes referred herein as each a “Party” and, collectively, the “Parties.”

WHEREAS, pursuant to the terms of (i) that certain Credit Agreement, dated as of October 31, 2011, between Grantor and Administrative Agent, among others (as amended, restated, modified or supplemented from time to time, the “Credit Agreement”), (ii) that certain Amended and Restated Guaranty Agreement, dated as of January 14, 2013, between Grantor and Administrative Agent, among others (as amended, restated, modified or supplemented from time to time, the “Guaranty Agreement”), (iii) that certain Amended and Restated Patent Security Agreement, dated as of October 31, 2011, between Grantor and Administrative Agent (as amended, restated, modified or supplemented from time to time, the “Amended Patent Security Agreement”), and (iv) that certain Patent Security Agreement, dated as of January 14, 2013, between Grantor and Administrative Agent (as amended, restated, modified or supplemented from time to time, the “Patent Security Agreement” and collectively with the Credit Agreement, Guaranty Agreement and Amended Patent Security Agreement, the “Security Agreements”), the Grantor granted to Administrative Agent a security interest in and to all of Grantor’s right, title and interest in and to the Patent Collateral (as defined in the Patent Security Agreement).

WHEREAS, the Patent Security Agreement was recorded with the United States Patent and Trademark Office on February 7, 2013, at patent assignment Reel 029777, Frame 0502.

WHEREAS, the Amended Patent Security Agreement was recorded with the United States Patent and Trademark Office on November 23, 2011, at patent assignment Reel 027278, Frame 0787.

WHEREAS, Grantor has satisfied in full the terms of the Security Agreements and requests a release of the Patent Collateral, and, effective nunc pro tunc as of the Effective Date, Administrative Agent wishes to fully terminate, discharge and release its lien and security interest in the Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged by the Parties, Administrative Agent hereby agrees for the benefit of Grantor, as follows:

1. Defined Terms. Unless otherwise defined herein, capitalized terms defined in the Security Agreements, have the meaning given to them in the applicable Security Agreement.
2. Release of Security Interest. Effective nunc pro tunc as of the Effective Date, the Administrative Agent agrees to fully terminate, release and discharge, and hereby does fully terminate, release, and discharge, its lien and security interest in all of each Grantor’s present and future right, title and interest in and to the Patent Collateral, including the following:

- a. all of the Patents and all Patent Licenses providing for the grant by or to the Grantor of any right under any Patent, referred to on **Schedule 1**, hereto;
- b. all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing; and
- c. all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

3. Further Assurances. Administrative Agent hereby authorizes the applicable Grantor to (i) record this Release with the USPTO, (ii) file UCC financing statement amendments with the applicable filing office in order to memorialize the release of the security interest of the Administrative Agent in the Released IP Collateral, and/or (iii) otherwise record or file this Release in the applicable foreign or domestic governmental office or agency. Administrative Agent hereby further agrees to duly execute, acknowledge, procure and deliver any further documents and to do such other acts, in each case at Grantor's expense, as may be reasonably necessary to effect the release of the security interest in the Released IP Collateral contemplated hereby.

4. Counterparts. This Release may be executed in any number of counterparts and by the different Parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original, and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Release electronically or by telecopy shall be as effective as delivery of a manually executed counterpart of this Release.

5. Successors and Assigns. This Release will be binding on and shall inure to the benefit of the Parties hereto and their respective permitted successors and assigns.


6. Severability. Each provision of this Release will be interpreted in such a manner as to be effective and valid under applicable law, but if any term or other provision of this Release is held to be invalid, illegal or unenforceable under applicable law, all other provisions of this Release shall remain in full force and effect.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Parties have caused this Release to be duly executed by its authorized representatives as of the Effective Date.


ADMINISTRATIVE AGENT:

CORTLAND CAPITAL MARKET SERVICES
LLC

By: 
Name: Emily Ergang Pappas
Title: Head of Legal, North America

GRANTOR:

KADMON CORPORATION, LLC

By: 
Name: Gregory Moss
Title: EVP, General Counsel

[Signature Page to Release]

Schedule I

See attached

SCHEDULE I
TO
PATENT SECURITY AGREEMENT

Kadmon Pharmaceuticals, LLC

Patents

A. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications pursuant to that certain Sub-License Agreement dated April 8, 2011 by and between Kadmon Corporation, LLC and NT Life Sciences, LLC. Such Patents and patent applications include:

Index No.	Country	Title	Application No.	Filing Date
1	P.C.T.	METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS	PCT/US06/06047	21-Feb-2006
2	P.C.T.	PHARMACOKINETICALLY IMPROVED COMPOUNDS	PCT/US06/06048	21-Feb-2006
3	P.C.T.	PHARMACOKINETICALLY IMPROVED COMPOUNDS	PCT/US06/11271	27-Mar-2006
7	Canada	METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS	2598270	21-Feb-2006

Index No.	Country	Title	Application No.	Filing Date
11	Eurasia	METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS	200701752	21-Feb-2006
13	Europe	METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS	6735624.6	21-Feb-2006
14	Georgia	METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS	AP2006010269	21-Feb-2006
19	Japan	METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS	2007-556391	21-Feb-2006
28	Ukraine	METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS	A200710355	21-Feb-2006

Index No.	Country	Title	Application No.	Filing Date
		COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS		
29	United States	METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS	11/884811	21-Feb-2006
34	Brazil	PHARMACOKINETICALLY IMPROVED COMPOUNDS	PI0608381-1	21-Feb-2006
35	Canada	PHARMACOKINETICALLY IMPROVED COMPOUNDS	2598271	21-Feb-2006
36	China	PHARMACOKINETICALLY IMPROVED COMPOUNDS	200680013057.9	21-Feb-2006
39	Eurasia	PHARMACOKINETICALLY IMPROVED COMPOUNDS	200701753	21-Feb-2006
42	Europe	PHARMACOKINETICALLY IMPROVED COMPOUNDS	6735625.3	21-Feb-2006
43	Georgia	PHARMACOKINETICALLY IMPROVED COMPOUNDS	2006010270	21-Feb-2006
47	Japan	PHARMACOKINETICALLY IMPROVED COMPOUNDS	2007-556392	21-Feb-2006
56	Ukraine	PHARMACOKINETICALLY IMPROVED COMPOUNDS	A200710356	21-Feb-2006
57	United States	PHARMACOKINETICALLY IMPROVED COMPOUNDS	12/570153	30-Sep-2009

Index No.	Country	Title	Application No.	Filing Date
61	Brazil	PHARMACOKINETICALLY IMPROVED COMPOUNDS	AWAITED	27-Mar-2006
62	Canada	PHARMACOKINETICALLY IMPROVED COMPOUNDS	2602254	27-Mar-2006
63	China	PHARMACOKINETICALLY IMPROVED COMPOUNDS	200680018211.1	27-Mar-2006
66	Eurasia	PHARMACOKINETICALLY IMPROVED COMPOUNDS	200702048	27-Mar-2006
68	Europe	PHARMACOKINETICALLY IMPROVED COMPOUNDS	6748799.1	27-Mar-2006
69	Georgia	PHARMACOKINETICALLY IMPROVED COMPOUNDS	AP2006010335	27-Mar-2006
72	India	PHARMACOKINETICALLY IMPROVED COMPOUNDS	7965/DELNP/2007	27-Mar-2006
73	Japan	PHARMACOKINETICALLY IMPROVED COMPOUNDS	2008-503293	27-Mar-2006
83	Ukraine	PHARMACOKINETICALLY IMPROVED COMPOUNDS	A200711701	27-Mar-2006
84	United States	PHARMACOKINETICALLY IMPROVED COMPOUNDS	11/887218	27-Mar-2006
88	Brazil	PHARMACOKINETICALLY IMPROVED COMPOUNDS	PI0716571.4	23-Aug-2007
89	Canada	PHARMACOKINETICALLY IMPROVED COMPOUNDS	2661483	23-Aug-2007
90	China	PHARMACOKINETICALLY IMPROVED COMPOUNDS	200780039772.4	23-Aug-2007
91	Europe	PHARMACOKINETICALLY IMPROVED COMPOUNDS	7837341.2	23-Aug-2007
96	India	PHARMACOKINETICALLY IMPROVED COMPOUNDS	1889/DELNP/2009	23-Aug-2007

Index No.	Country	Title	Application No.	Filing Date
97	Japan	PHARMACOKINETICALLY IMPROVED COMPOUNDS	2009-525652	23-Aug-2007
101	P.C.T.	PHARMACOKINETICALLY IMPROVED COMPOUNDS	PCT/US07/18784	23-Aug-2007
105	Ukraine	PHARMACOKINETICALLY IMPROVED COMPOUNDS	A200902506	23-Aug-2007
106	United States	PHARMACOKINETICALLY IMPROVED COMPOUNDS	12/438504	23-Aug-2007
110	Canada	PROTEIN KINASE INHIBITORS	2700988	27-Sep-2007
112	P.C.T.	PROTEIN KINASE INHIBITORS	PCT/US07/21093	27-Sep-2007
115	United States	PROTEIN KINASE INHIBITORS	12/836414	14-Jul-2010
119	Canada	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION	2,605,510	19-Apr-2006
125	Eurasian Patent Org.	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION	200702271	19-Apr-2006
126	European Patent Convention	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION	06751011.5	19-Apr-2006
127	Georgia	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION	P4878 (Granted)	19-Apr-2006
131	Japan	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION	2008-507927	19-Apr-2006

Index No.	Country	Title	Application No.	Filing Date
142	Ukraine	BITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION	a200712815	19-Apr-2006
144	United States	BITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION	11/407,500	19-Apr-2006

B. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to MMP-14 antibodies pursuant to that certain License Agreement dated September 16, 2012 by and between Kadmon Corporation, LLC and Dyax Corp.. Such Patents and patent applications include:

L&A No.		Application No.	Patent No.	Publication No.	Application Title	Status	Filing Date
D2033-7087	AU	2006332713			METALLOPROTEINASE BINDING PROTEINS	Pending	29-Dec-2006
D2033-7087	CA	2635588			METALLOPROTEINASE BINDING PROTEINS	Pending	29-Dec-2006
D2033-7087	EP	06848335.3		1981538	METALLOPROTEINASE BINDING PROTEINS	Published	29-Dec-2006
D2033-7087	HK	09103460.6		1123740	METALLOPROTEINASE BINDING PROTEINS	Published	29-Dec-2006
D2033-7087	IN	6573/DELNP/08			METALLOPROTEINASE BINDING PROTEINS	Pending	29-Dec-2006
D2033-7087	JP	2008-548766			METALLOPROTEINASE BINDING PROTEINS	Pending	29-Dec-2006
D2033-7087	00	60/755376			METALLOPROTEINASE BINDING PROTEINS	Expired	30-Dec-2005
D2033-7087	01	60/805567			METALLOPROTEINASE BINDING PROTEINS	Expired	22-Jun-2006

D2033-7087	02	60/870566			METALLOPROTEINASE BINDING PROTEINS	Expired	18-Dec-2006
D2033-7087	10	11/648423	7745587	0217997A1	ANTIBODIES THAT BIND MMP-14	Granted	29-Dec-2006
D2033-7087	20	12/776195	8106168	US-2010-0266490-A1	METALLOPROTEINASE BINDING PROTEINS	Granted	07-May-2010
D2033-7087	21	13/335185		US-2012-0107231-A1	METALLOPROTEINASE BINDING PROTEINS	Published	22-Dec-2011
D2033-7087	WO	PCT/US2006/049566		079218A3	METALLOPROTEINASE BINDING PROTEINS	Inactive	29-Dec-2006
D2033-7102	00	61/025017			EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER	Expired	31-Jan-2008
D2033-7102	01	61/467305			EVALUATING PROTEIN EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER	Expired	24-Mar-2011
D2033-7102	10	12/337218	8183008	US-2009-0203060-A1	EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER	Granted	17-Dec-2008

D2033-7102	40	13/454534			EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER	Pending	24-Apr-2012
D2033-7102	WO	PCT/US2008/087230		079581A1	EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER	Inactive	17-Dec-2008
D2033-7104	00	61/024703			METALLOPROTEINASE BINDING PROTEINS	Expired	30-Jan-2008
D2033-7104	WO	PCT/US2009/032384		097397A3	METALLOPROTEINASE BINDING PROTEINS	Inactive	29-Jan-2009
D2033-7106	AU	2008338421			COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS	Pending	17-Dec-2008
D2033-7106	CA	2707637			COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS	Pending	17-Dec-2008
D2033-7106	EP	08862358.2		2231186	COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS	Published	17-Dec-2008

D2033-7106	HK	11102502.4		1148227	COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS	Published	17-Dec-2008
D2033-7106	IN	5139/DELNP/2010			COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS	Published	17-Dec-2008
D2033-7106	JP	2010-539749			COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS	Pending	17-Dec-2008
D2033-7106	00	61/025032			COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 INHIBITORS BINDING PROTEINS	Expired	31-Jan-2008
D2033-7106	10	12/337140	8147836	US-2009-0186031-A1	COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS	Granted	17-Dec-2008
D2033-7106	40	13/338622		US-2012-0141473-A1	COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS	Published	28-Dec-2011

D2033-7106	WO	PCT/US2008/087236		079585A3	COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS	Inactive	17-Dec-2008
D2033-7116	00	61/047787			METHODS AND COMPOSITIONS COMPRISING ANTI-IDIOTYPIC ANTIBODIES TO ANTI-MMP-14-ANTIBODIES	Expired	25-Apr-2008
D2033-7116	10	12/429338		0275124 A1	METHODS AND COMPOSITIONS COMPRISING ANTI-IDIOTYPIC ANTIBODIES TO ANTI-MMP-14-ANTIBODIES	Abandoned	24-Apr-2009
D2033-7116	WO	PCT/US2009/041632		132251A3	METHODS AND COMPOSITIONS COMPRISING ANTI-IDIOTYPIC ANTIBODIES TO ANTI-MMP-14-ANTIBODIES	Inactive	24-Apr-2009
D2033-7128	AU	2009308369			COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS	Pending	22-Oct-2009
D2033-7128	CA	2741492			COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS	Pending	22-Oct-2009

D2033-7128	EP	09822726.7		2350305	COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS	Published	22-Oct-2009
D2033-7128	HK	12101008.4		1160668	COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS	Published	22-Oct-2009
D2033-7128	JP	2011-533344			COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS	Pending	22-Oct-2009
D2033-7128	00	61/107384			COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS	Expired	22-Oct-2008
D2033-7128	US	13/124046		US-2011-0262396-A1	COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS	Published	22-Oct-2009
D2033-7128	WO	PCT/US2009/061717		048432A1	COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS	Inactive	22-Oct-2009

D2033-7141	00	61/549873			COMBINATION THERAPY COMPRISING AN MMP-14 BINDING PROTEIN	Pending	21-Oct-2011
------------	----	-----------	--	--	--	---------	-------------

C. Kadmon Corporation, LLC has acquired exclusive rights in and to certain patent applications related to avasimibe pursuant to that certain Exclusive License Agreement dated November 21, 2011 by and between Kadmon Corporation, LLC and The J. David Gladstone Institutes. Such patent applications include:

Method of Treating Hepatitis C Virus Infection

US Serial Number 13/078,344 Publication Number US2011/0243894 A1

Europe: EP 09818423.7

D. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to salirasinib pursuant to that certain Asset Purchase Agreement dated December 16, 2011 by and between Kadmon Corporation, LLC and Concordia Pharmaceuticals, Inc.. Such Patents and patent applications include:

Country	Application Number	Patent Number	Title	Status
Canada	2577310	2577310	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
European Patent Convention	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
European Patent Convention	10004111.0		METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Filed
European Patent Convention	10183723.5		METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Filed
France	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
Germany	05787786.2	602005021115.2 (EP1778209)	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
Great Britain	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
Hungary	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted

Ireland	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
Italy	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
Mexico	MX/a/2007/001929	278624	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
Poland	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
Spain	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
Sweden	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
Switzerland	05787786.2	EP1778209	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
United States	60/602,361		METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Expired
United States	11/659,582		METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Filed

Title	Inventors	Application Date	Application Num	Country	Patent No	Patent Date
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	10/11/1994	95905295.2	SWEDEN	0729354	6/2/2002
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	12/11/1993	107587	ISRAEL	107587	17/11/1998
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	10/11/1994	95905295.2	EUROPE	0729354	6/2/2002
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	10/11/1994	2,176,373	CANADA	2,176,373	24/3/2009

FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITIONS CONTAINING THEM	Kloog Yoel - Life Sciences	10/11/1994	5140078/95	JAPAN	3757236	13/1/2006
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	10/11/1994	08/338,764	U.S.A	5,705,528	6/1/1998
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	10/4/2005	11/093,255	U.S.A	RE39,682	5/6/2007
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	10/11/1994	95905295.2	FRANCE	0729354	6/2/2002
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	10/11/1994	95905295.2	GERMANY	0729354	6/2/2002
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	10/11/1994	95905295.2	SWITZERLAND	0729354	6/2/2002
FARNESYL DERIVATIVES AND PHARMACUTICAL COMPOSITION CONTAINING THEM	Kloog Yoel - Life Sciences	10/11/1994	95905295.2	UNITED KINGDOM	0729354	6/2/2002

NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS	Kloog Yoel - Life Sciences,Chapman Joab - Medicine- Sackler Faculty,Bruck Rafael - Medicine- Sackler Faculty,Reif Shimon - Medicine- Sackler Faculty,Karussis Dimitrius ,Brownstein Michael J.	19/6/2000	PCT/US00/16863	PCT TREATY		
NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS	Kloog Yoel - Life Sciences,Chapman Joab - Medicine- Sackler Faculty,Bruck Rafael - Medicine- Sackler Faculty,Reif Shimon - Medicine- Sackler Faculty,Karussis Dimitrius ,Brownstein Michael J.	19/6/2000	09/597,332	U.S.A	6,462,086	8/10/2002
TREATMENT OF POST- ANGIOPLASTY RESTENOSIS AND ATHEROSCLEROSIS WITH RAS ANTAGONISTS	Kloog Yoel - Life Sciences,George Jakob - Medicine- Sackler Faculty,Keren Gad - Medicine-Sackler Faculty	22/4/2003	10/420,682	U.S.A	6,946,485	20/9/2005
TREATMENT OF LUNG CANCER	Kloog Yoel - Life Sciences,Haklai Roni - Life Sciences,Zundelevich Adi - Life Sciences	19/12/2006	60/875,915	US Provisional		
TREATMENT OF LUNG CANCER	Kloog Yoel - Life Sciences,Haklai Roni - Life Sciences,Zundelevich Adi - Life Sciences	17/12/2007	12/519,578	U.S.A		

TREATMENT OF LUNG CANCER	Kloog Yoel - Life Sciences,Haklai Roni - Life Sciences,Zundeleovich Adi - Life Sciences	17/12/2007	PCT/IL2007/001556	PCT TREATY		
TREATMENT OF LUNG CANCER	Kloog Yoel - Life Sciences,Haklai Roni - Life Sciences,Zundeleovich Adi - Life Sciences	17/12/2007	7849582.7	EUROPE	2094260	
TREATMENT OF LUNG CANCER	Kloog Yoel - Life Sciences,Haklai Roni - Life Sciences,Zundeleovich Adi - Life Sciences	17/12/2007	2,672,839	CANADA		
TREATMENT OF LUNG CANCER	Kloog Yoel - Life Sciences,Haklai Roni - Life Sciences,Zundeleovich Adi - Life Sciences	17/12/2007	MX/a/2009/006574	MEXICO		1/2/2012
TREATMENT OF LUNG CANCER	Kloog Yoel - Life Sciences,Haklai Roni - Life Sciences,Zundeleovich Adi - Life Sciences	17/12/2007	07849582.7	GERMANY	2094260	
TREATMENT OF LUNG CANCER	Kloog Yoel - Life Sciences,Haklai Roni - Life Sciences,Zundeleovich Adi - Life Sciences	17/12/2007	07849582.7	FRANCE	2094260	
TREATMENT OF LUNG CANCER	Kloog Yoel - Life Sciences,Haklai Roni - Life Sciences,Zundeleovich Adi - Life Sciences	17/12/2007	07849582.7	UNITED KINGDOM	2094260	1/2/2012

						1/2/2012
ALKOXYALKYL S-PRENYLTHIOSALICYLATES FOR TREATMENT OF CANCER	Kloog Yoel - Life Sciences, Bauer Victor J. ,Goldberg Liat - Life Sciences	28/1/2009	61/206,108	US Provisional		1/2/2012
ALKOXYALKYL S-PRENYLTHIOSALICYLATES FOR TREATMENT OF CANCER	Kloog Yoel - Life Sciences, Bauer Victor J. ,Goldberg Liat - Life Sciences	20/1/2010	12/690,174	U.S.A		
CANCER THERAPY WITH COMBINATIONS OF FTS WITH HDAC INHIBITORS	Kloog Yoel - Life Sciences, Haklai Roni - Life Sciences, Brownstein Michael J. ,Biran Anat - Life Sciences	26/10/2009	61/254,872	US Provisional		
CANCER THERAPY WITH COMBINATIONS OF FTS WITH HDAC INHIBITORS	Kloog Yoel - Life Sciences, Haklai Roni - Life Sciences, Brownstein Michael J. ,Biran Anat - Life Sciences	26/10/2010	PCT/US2010/054042	PCT TREATY		
CANCER THERAPY WITH COMBINATIONS OF FTS WITH HDAC INHIBITORS	Kloog Yoel - Life Sciences, Haklai Roni - Life Sciences, Brownstein Michael J. ,Biran Anat - Life Sciences	26/10/2010		JAPAN		
TREATMENT OF MULTIPLE SCLEROSIS	Kloog Yoel - Life Sciences, Chapman Joab - Medicine-Sackler Faculty, Aizman Elizabeta - Life Sciences	13/1/2010	61/294,603	US Provisional		

TREATMENT OF MULTIPLE
SCLEROSIS

Kloog Yoel - Life
Sciences, Chapman
Joab - Medicine-
Sackler
Faculty, Aizman
Elizabeta - Life
Sciences

13/1/2011

PCT/IB2011/000213

PCT TREATY

